An investigational gene therapy has shown to slow the progression of Huntington's disease. The therapy's path to regulatory approval is uncertain, with reports of both positive trial results and the need for additional data. The FDA's stance on the therapy is unclear, with some outlets indicating a review meeting has been scheduled, while others suggest the agency has changed its position or is requiring more information.